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ABSTRACT 
OBJECTIVE 
The study was conducted to compare the efficacy of 
Intravenous Ondansetron (4mg) Versus Intravenous Palonosetron 
(75 mcg) in the Prevention of Postoperative Nausea and Vomiting 
in Laparoscopic Gynaecological Surgeries. 
METHODOLOGY 
100 patients were randomly assigned into two groups of 50 
patients. One group of 50 patients received Intravenous 
Ondansetron (4mg) and the other group of 50 patients received 
Palonesetron 75mcg intravenously before induction of Anaesthesia.  
RESULT 
The two groups were found to be similar with respected to 
Age, Weight, ASA Physical Status, Duration of Surgery and 
Anaesthesia. There was no significant difference in the incidence of 
nausea and vomiting between the two groups in the first 0-2hours. 
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However the incidence of vomiting was significantly reduced in the 
next 2-48 hours in the Palonesetron group when compared to 
Ondansetron group. The incidence of drug related adverse effects 
was not statistically significant. 
CONCLUSION 
Palonosetron was superior to Ondansetron in the prevention 
of post operative nausea and vomiting and hence it is safe and 
reliable to use without any serious adverse effects. 
Key Words: Palonosetron, Ondansetron, Post Operative 
Nausea and Vomiting. 
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 “BIG LITTLE PROBLEM TO THE 
ANAESTHESIOLOGIST” 
INTRODUCTION 
Post Operative Nausea and Vomiting is defined as the 
occurrence of nausea, retching or vomiting during first 24-48 
hours after surgery. Post Operative Nausea and Vomiting is 
the second most common complaint next to pain in the post-
operative period.  
In the Era of Advanced Medicine and improved Post 
Operative care, Nausea and Vomiting in postoperative  period 
is a distressing complication which needs attention and 
prevention. 
Of various pathways  and triggering factors that have 
been postulated so far, no exact etiology has been defined.  
Numerous factors have been identified in association 
with Post Operative Nausea and  vomiting such as patient 
age, gender, type of surgery, duration of surgery, anaesthestic 
factors, smoking, History of motion Sickness, etc. 
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Among the anaesthesia risk factors inhaled anaesthetics 
and opiods are the common triggering agents associated with 
post operative nausea and vomiting. 
Post operative nausea and vomiting being an unpleasant 
experience subjectively, is also associated with very serious 
adverse complication such as aspiration, wound and suture 
dehiscence in case of major abdominal surgeries, esophageal 
rupture, subcutaneous emphysema, pneumothorax. 
Post operative nausea and vomiting was found to be the 
common indication for hospital readmission following day 
care surgery. 
Hence the hunt for an effective antiemetic, thirst for a 
greater understanding and insight in the prevention and 
treatment of post operative nausea and vomiting is reflected 
in the numerous studies that has been conducted so far.  
Currently available antiemetic drugs include Dopamine 
antagonist such as Metoclopramide, Droperidol, haloperidol, 
H1 receptor antagonist, such as cyclizine, promethazine, 
anticholinergic such as Atropine and hyoscine, 5HT3 receptor 
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antagonist such as Ondansetron, Dolasetron, Granisetron, 
Tropisetron. 
Dexamethasone is a proven antiemetic and its 
mechanism of action is still unknown. 
Recently FDA approved aprepitant, a NK-1 receptor 
antagonist as antiemetic. In the near future, other NK-1 
receptor antagonist that is still under trial is expected to enter 
the market. 
Currently 5HT3 receptor Antagonist is considered to be 
superior to other class of drugs in the prevention of post 
operative nausea and vomiting but none of the drug is potent 
enough to completely prevent the incidence of post operative 
nausea and vomiting. Hence multimodal intervention is 
advocated in high risk patients susceptible to post operative 
nausea and vomiting. 
5HT3 receptor antagonist is currently used as first-line 
antiemetic. Among 5HT3 receptor antagonist second 
generation drug palonosetron was found to be the most 
effective drug. Very few studies have been carried out to 
prove the efficacy and potency of this drug.  
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AIM 
The aim of this single blinded interventional 
prospective study is to compare the effectiveness of 
intravenous ondansetron (4mg) vs intravenous palonosetron 
(0.075mg) in the prevention of post operative nausea and 
vomiting in patients undergoing laparoscopic gynaecological 
surgery under general anaesthesia. 
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PHYSIOLOGY OF NAUSEA AND VOMITING 
NAUSEA 
Nausea is defined as an unpleasant sensation with an urge to 
vomit. It presents with salivation, pallor, sudden cold sweat, 
followed by reduced gastric tone and contraction of duodenum. It 
generally precedes vomiting. 
RETCHING 
It is a strong involuntary effort to vomit and it usually 
occurs following nausea. The abdominal muscles, diaphgram 
and chest wall are the muscles actively involved in retching 
.Expulsion of gastric contents do not occur in retching. 
VOMITING 
Vomiting is defined as the forceful expulsion of gastric 
contents through mouth. It is considered to be a defense 
mechanism to expel the noxious substance present in the 
intestine. Stomach does not actively take part in vomiting. It 
is the relaxation of lower esophagel sphincter aided by the 
active involvement of the diaphgram and the abdominal 
muscles that facilitates vomiting. 
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Physiology of post operative nausea and vomiting is 
complex and it is not completely understood. Recent studies 
have shown that the brain structures associated with vomiting 
is present throughout the medulla oblongata and it is not 
localized to any anatomically defined vomiting center. It 
includes chemoreceptor trigger zone (CRTZ) located in the 
area postrema at caudal end of the fourth ventricle and the 
nucleus tractus solitaries which is present in the area 
postrema and lower pons. 
Chemoreceptor trigger zone is not protected by Blood 
brain barrier. It receives afferents from the vagus and it can 
detect toxins and metabolites with emetogenic potential and 
also the drugs circulating in the blood and cerebrospinal 
fluid. 
Chemoreceptor trigger zone projects neurons to 
Nucleus Tractus Solitarius which in turn receives vagal 
afferents and also inputs from limbic and vestibular system.  
Efferent from Nucleus Tractus Solitarius stimulate the 
ventral respiratory group and dorsal motor nucleus of vagus, 
nucleus ambiguous and rostral nucleus to induce vomiting. 
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Stimulus from the extra medullary center such as limbic 
system and vestibular system also induces nausea and 
vomiting as seen in motion sickness, meneire’s disease. 
Psychological stimulus such as anxiety, pain and fear  can also 
induce nausea and vomiting. 
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PATHWAY OF NAUSEA AND VOMITING  
Toxic substance in the gut stimulates the release of 5HT 
from enterochromaffin cell which constitutes 90% reserve of 
the total 5-HT in our body. 5-HT is released in close 
proximity to the vagal afferent. Nucleus Tractus Solitarius 
receiving afferent from vagus induces vomiting. Vagal 
afferents are of two types. 
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Mechanoreceptors in the muscular layer is activated by 
contraction and distension of the muscular wall of the gut. 
Chemoreceptor in the lumen of the gut responds to noxious 
substance in the gut. 
Absorbed toxin and drugs stimulate CRTZ, a 
circumventricular organ which lacks Blood brain barrier, 
which in turn triggers Nucleus Tractus Solitarius in the 
Brainstem to induce vomiting. 
Numerous receptors are identified in the CRTZ. But it 
is still unclear why the agonist can’t induce vomiting whereas 
the antagonist is effective in preventing vomiting. 
Serotonin is also released by stimulation of M3 
receptors, Beta adrenoceptors and H3receptors. The 
stimulation of GABA B receptors, 5-HT4 receptor and Alpha 
2 adrenoceptor and Vasoactive Intestinal Polypeptide & 
Somatostatin was found to reduce the release of serotonin. 
Post Operative Nausea and Vomiting after major 
abdominal surgery is attributed to the release of serotonin 
which is evident by the presence of metabolite, 5-Hydroxy 
acetic acid in the urine. 
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Stimulation of vestibular system results in emesis as 
seen in motion sickness, meniere’s disease.   
Head injury, infection of the meninges and brain, space 
occupying lesion in the brain which usully presents with 
increased intracranial pressure usually presents with nausea 
and vomiting. 
Acute metabolic changes such as high blood sugar and 
rampant hormonal changes that occurs in pregnancy also 
induces nausea and vomiting. 
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FACTORS ASSOCIATED WTH POST OPERATIVE 
NAUSEA AND VOMITING 
PATIENT RELATED FACTORS:- 
Gender 
 Female gender is an independent risk factor for 
Post Operative Nausea and Vomiting. Incidence of Post 
Operative Nausea and Vomiting is two to three times higher 
in woman than in men. 
Age 
Incidence of post-operative nausea and vomiting 
increases with age. It is least in infants , increases until  late 
childhood and remains constant in adults. 
Body Habitus 
Incidence of post-operative nausea and vomiting is 
greater in obese than in asthenic patients. 
Smoking 
Non-smokers were 1.8 times more likely than smokers 
to have post-operative nausea and vomiting. Nicotine 
stimulates indirect GABA mediated cerebral dopamine 
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release. Reduced incidence of post-operative nausea and 
vomiting in smokers is attributed to the withdrawal of 
nicotine in the perioperative period which results in low 
dopamine levels. 
History of post-operative nausea and vomiting, motion 
sickness and migraine are independent predictors of post-
operative nausea and vomiting. 
ANAESTHESIA RELATED FACTORS: 
Regional Vs General Anaesthesia 
General Anaesthesia is associated with high incidence 
of nausea and vomiting when compared with Regional 
Anesthesia.  
General Anaesthesia is attributed to the high incidence 
of post-operative nausea and vomiting probably due to use of 
numerous drugs and anaesthetic gases. Among the induction 
agents, propofol is associated with lower incidence of post -
operative nausea and vomiting and it has antiemetic property 
at low does.Use of Ketamine is significantly associated with 
nausea and vomiting in the post operative period.  
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Nitrous oxide is also an highly emetogenic gas which 
when used in combination with volatile anesthetic is found to 
have  additive emetogenic effect. 
All the volatile anaesthetics that are currently in use are 
emetogenic and severity of individual volatile anaesthetic has 
not been elucidated so far. 
Opioids 
The superior quality of analgesia obtained from the  
opioids makes it the most needed drug of choice for 
Anaesthesiologist who are dealing with pain management. 
One of the most common side effect of opioids is nausea and 
vomiting   
Increased usage of opioids such as morphine and 
fentanyl for analgesia is  associated with nausea and vomiting 
in the post-operative period. 
Meta analysis of various studies shows that irrespective 
of the type of opioid, the dose of opioids is an important 
determinant factor for post-operative nausea and vomiting. 
Duration of Anaesthesia is also an independent risk 
factor for post-operative nausea and vomiting. Longer 
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duration of surgery implies longer duration of anesthesia and 
the use of volatile agents itself is an independent risk factor 
for post-operative nausea and vomiting.The incidence of post-
operative nausea and vomiting is high in invasive procedures. 
Bag and mask ventilation results in gastric distension 
and induces emesis due to entrapment of air in the stomach.  
Airway manipulation during laryngoscopy ,intubation 
and extubation will result in mechanoreceptor stimulation via 
vagus and glossopharyngeal nerve resulting in emesis. 
Neuromuscular reversal using neostigmine, an 
anticholinesterase inhibitor is associated with post-operative 
nausea and vomiting. 
Sudden and rapid movement of head and neck while 
shifting the patient can induce nausea and vomiting. 
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SURGERY RELATED FACTORS 
The incidence of post-operative nausea and vomiting 
depends on the type of surgery as well. Middle ear  surgeries, 
ENT surgeries such as adenotonsillectomy and surgery 
involving the larynx which are frequently associated with 
swallowing of blood is associated with high incidence of 
post-operative nausea and vomiting. 
Major abdominal surgery which are associated with 
large release of serotonin from the gut, peritoneal irritation in 
laparoscopic surgery and vagal stimulation in gynaecological 
procedures are also attributed to the incidence of nausea and 
vomiting in post operative period following these surgeries.  
Middle ear surgeries such as Tympanoplasty  done 
under general anaesthesia results in diffusion of nitrous oxide  
and rise in the middle ear pressure .This results in the 
stimulation of vestibular afferents which results in vomiting. 
Arnold’s nerve, auricular branch of vagus nerve which 
supplies the tympanum also induces emesis when stimulated.  
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PERIOPERATIVE FACTORS 
Anxiety and stress increases the risk of post-operative 
nausea and vomiting which is mainly due to release of 
adrenaline and gastric distension as a result of swallowing of 
air.  
In patient with delayed gastric motility, such as 
diabetes mellitus and pyloric stenosis, risk of post-operative 
nausea and vomiting is high. 
Induction of anaesthesia shortly after the intake of food 
is found to be associated with post-operative nausea and 
vomiting. This is attributed to the increased release of 
serotonin in the hepatic circulation following a meal.  
Since Post-operative nausea and vomiting is attributed 
to multiple risk factors, predictive risk score have been 
defined based on meta analysis of various studies  
Koivuranta et al . , proposed a simplified risk score for 
children. The parameters in the risk stratification includes 
female gender, non smoking status, history of post-operative 
nausea and vomiting, history of motion sickness and duration 
of surgery >60min. If 0,1,2,3,4 or 5 risk factors are present, 
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the risk of incidence of post-operative nausea and vomiting is 
17%, 18%, 42%, 54%, 74% and 87% respectively.  
Apfel et al ., defined a simplified risk scoring system 
for adult. Apfel’s risk score consist of 4 factors instead of 5 
in koivuranta et al. Apfel’s risk score includes female gender, 
history of post-operative nausea and vomiting, motion 
sickness, non smoking status and post-operative use of 
opiods. If 0,1,2,3 & 4 factors are present, the risk of nausea 
and vomiting in post-operative is 10%, 20%, 40%, 60%or 
80% respectively. 
POVOC score is another simplified risk score for 
predicting post-operative nausea and vomiting is children, it 
includes duration of surgery >30 min, age > 3 years, 
strabismus surgery and history of post-operative vomiting in 
the child / relatives. If 0,1,2,3 and 4,  risk factors are present 
the incidence of post-operative nausea and vomiting is 
9%,10%,30% 55% and 70% respectively. 
Antiemetic prophylaxis differs from patient to patient  
based on the presence of risk factors. 
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Hence the risk of nausea and vomiting in post operative  
can be best predicted by simplified score rather than 
assessing the numerous risk factors. 
This implies to the post operative nausea and vomiting 
prophylaxis strategy as well. It should be tailored based on 
the patient risk factors. Such high risk patient gets absolute 
risk reduction from effective intervention. 
ANTIEMETICS 
Currently used antiemetics in the prevention and  
management of Post Operative Nausea and Vomiting includes 
Dopamine antagonist such as metoclopramide, Droperidol, 
Haloperidol, Alizapride, Perphenazine, and prochlorperazine, 
H1 receptor antagonist such as Dimenhydrinate, cyclizine, 
and promethazine, anticholinergics  include hyoscine, 
atropine, serotonin receptor antagonist namely ondansetron, 
dolasetron, granisetron, tropisetron and GABA receptor 
agonist diazepam, lorazepam and Midazolam.Recently, 
neurokinin 1 receptor antagonist aprepitant is added to the  
class of antiemetics. Dexamethasone is also used in the 
prevention of nausea and vomiting. The mechanism of action 
is still not known. 
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DOPAMINE ANTAGONIST 
Dopamine antagonist exerts its antiemetic effect via D2 
receptor. Metoclopramide was initially used in the treatment 
of chemotherapy induced nausea and vomiting. Based on 
clinical studies, 10mg was found to be effective in the 
prevention of Post Operative Nausea and Vomiting. Large 
doses is associated with side effects such as hypotension, 
tachycardia and other notable side effects such as dyskinesia 
and extrapyramidal symptoms. 
Droperidol, a potent D2 antagonist has antiemetic effect 
in the dose range of 0.625-1.25mg. Even with minimal dose, 
side effects such as anxiety, akasthisia, dystonia and 
restlessness can occur. Droperidol is contraindicated in 
patients with long Q-T interval. FDA gave black box warning 
to haloperidol in view of arrythmias in patients with long QT 
syndrome. 
Other Dopamine antagonist such as Alizapride, 
Prochlorperazine and perphenazine are not routinely used.  
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HISTAMINE ANTAGONIST 
H1 receptor antagonist, Diphenhydramine and 
Dimenhydrinate which are used in the treatment of motion 
sickness  posses anticholinergic activity as well. All H1 
antagonist have sedation as the most common side effect. 
other Side effects include  headache, urinary retention dry 
mouth, blurred vision and drowsiness. vascular necrosis, a 
very rare and infrequent complication have also been 
documented. 
ANTICHOLINERGICS 
Atropine was found to be more effective in preventing 
nausea and vomiting than glycopyrolate. It is useful in motion 
induced nausea and vomiting as well. Scopolamine, a short 
acting anticholinergic which is also an effective antiemetic is 
associated with increased incidence of side effects such as 
dry mouth, agitation, blurring of vision and dizziness. 
DEXAMETHASONE 
Dexamethasone exerts its pharmacological antiemetic 
effect through central inhibition of nucleus tractus solitarius. 
It has a slow onset of action and its efficacy is similar to 
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ondansetron. It is effective in very low dose of 2-5mg 
intravenously. 
NEUROKININ ANTAGONIST 
Neurokinin 1 receptors are found in the vagal afferents 
in the gut. substance P, a regulatory polypeptide induces 
emesis via neurokinin receptors present in vagus. Aprepitant, 
NK 1 receptor antagonist is currently in use as an antiemetic. 
Other drugs of this class, Casopitant and Rolapitant is 
expected to enter the market shortly. 
OTHER ADJUVANT THERAPIES 
Ginger is assumed to have antiemetic property but 
studies have not proved any definite mechanism of action. 
Infusion of liberal crystalloids and adequate hydration was 
found to reduce the incidence of nausea. 
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5HT3 RECEPTOR ANTAGONIST AND POST 
OPERATIVE NAUSEA AND VOMITING 
5-HT3 receptor antagonist is considered to be superior 
among the available class of antiemetics.Serotonin receptor 
antagonist drugs are highly selective drugs that acts only on 
5HT3 receptors sparing other cholinergic, histamine and 
dopamine receptors. When compared to the other available 
antiemetics , this group of drug is found to be more potent 
with minimal sideeffects. 5-HT3 receptors are present in 
vagal afferents, the nucleus tractus solitarius and the area 
postrema. Eventhough all 5-HT3 receptor antagonist have 
same mechanism of action they have difference in affinity at 
the receptor level due to the difference in the chemical 
structure.All the drugs in this group are metabolized by 
cytochrome P450 in different path ways. 
Ondansetron, a carbazole derivative is a strong 
antagonist of 5-HT3 receptor with weak 5-HT4 antagonistic 
activity.It has a half life of 3.9 hours and it is metabolized by 
CYP1A1/2,CYP2D6,CYP3A3/4/5. The drug is administered 
at a dose of 0.15mg per Kg. 
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Granisetron is a indazole derivative with 5-HT3 
receptor antagonistic activity.It undergoes metabolism by 
CYP3A3/4/5 and it has a half life of 9-11 hours.The dosage 
of the drug is 10 microgram per Kg. 
Dolasetron, a indole derivative with a half life of 7-9 
hours is a selective 5-HT3 receptor antagonist. It undergoes 
metabolism similar to Granisetron and also by  CYP2D6. It is 
administered at a dose of 0.6 – 3 mg per Kg. 
Palonosetron, an isoquinoline derivative drug has 
highest affinity for 5-HT3 receptor among all 5-HT3 receptor 
antagonist. The unusual and prolonged half life of around 40 
hours makes this drug distinct among 5-HT3 receptor 
antagonist.Palonosetron is metabolized by Cytochrome P450 
(CYP1A2, CYP2D6, CYP3A3/4/5). This drug was commonly 
used in the prevention of chemotherapy indused nausea and 
vomiting at a dose of 0.25mg single intravenous bolus. 
Ramosetron with selective action only at 5-HT3 
receptor is a benzimidazole derivative, with a half life of 
around 6 hours.The metabolic pathway has not been clearely 
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elucidated so far.It is administered at a dose of 300 micogram 
per Kg. 
  Tropisetron is an indole derivative with selective action only 
at 5-HT3 receptor and it is used in the dose of 200 microgram 
per Kg. It is metabolized by CYP3A3/4/5, CYP2D6 with a 
half life of 5.6 hours. 
Serotonin receptor antagonist have been associated with 
very few side effects such as headache, constipation and 
dizziness. It does not produce unwanted side effects like 
sedation and extrapyramidal symptoms which is seen with 
antihistamine drugs.  
A very rare and infrequent adverse effect of serotonin 
receptor antagonist is the incidence of cardiovascular rythym 
abnormalities like prolongation of PT and QT interval in 
electrocardiogram. 
Serotonin receptor antagonist is used in the 
management of chemotherapy induced nausea and vomiting 
and post operative nausea and vomiting.It is not effective in 
motion sickness. 
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5-HT3 receptor antagonist  is currently preferred as the 
first line of antiemetic in the management of post operative 
nausea and vomiting due to its high receptor selectivity and 
minimal side effects. 
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PHARMACOLOGY OF ONDANSETRON 
Ondansetron is a selective 5-HT3 receptor antagonist.It 
is chemically 1, 2, 3, 9 tetrahydro 9-methyl-3-[ (2-methyl-1 H 
imidazole-1-ylmethyl-4H-Carbazol-4-one  
monohydrochloride dihydrate  (C18 H19 N3O. Hcl-2H20). 
It’s estimated molecular weight is 365.9.  
 
PHYSICAL PROPERTIES 
Ondansetron hydrochloride is a white to off-white 
powder obtained by chemical synthesis. It is soluble in water 
(3.2/W/W) and in 0.9% Sodium chloride (0.8% W/V). The 
drug dosage is expressed in milligram. 
 
 
 30 
PHARMACODYNAMICS 
Serotonin receptors are distributed both centrally and 
peripherally. ondansetron is primarily a 5HT3 receptor 
antagonist. Ondansetron’s antiemetic action is still unclear 
whether it is mediated via central receptor or peripheral 
receptors or both .It has no effect on gut motility, small 
intestine transit time or its sphincter tone. Interaction of 
ondansetron with general and local anesthetics  is not known. 
Ondansetron does not have any effect on respiratory 
depressant effect induced by narcotics. 
It does not have interaction with any muscle relaxants 
and does not alter the degree of neuromuscular blockade 
produced by non-depolarising relaxants. 
PHARMACOKINETICS 
It is administered by Oral / Parentral  (intravenous / 
intramuscular) route. It is completely absorbed from the 
gastro intestinal tract after oral uptake and it does not 
accumulate with repeated administration. Intake of drug after 
a meal is found to increase the bioavailability. The plasma 
concentration of the drug reaches peak concentration after 0.5 
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to 2 hours since the time of intake. Due to first pass 
metabolism in liver, bio-available of the drug is only about 
60%.Other routes of administration include intramuscular, 
subcutaneous and rectal administration. 
Plasma half life of ondansetron is 3-4 hours and the rate 
of clearance is 541ml/min and it is reduced with increasing 
age and hepatic impairment. Dosage needs to be reduced in 
old age because of increased bioavailability due to reduced 
first-pass hepatic metabolism and a prolonged half life of 4-5 
hours. 
Volume of distribution of drug is approximately around 
160L and it moderately binds to plasma proteins (70 to 
76%).Pediatric age groups and patients with hepatic disease 
have large volume of distribution. 
It crosses the blood-brain barrier and concentration of the 
drug in cerebrospinal fluid measures about 10% of the plasma 
concentration. 
95% of the drug undergoes metabolism in the liver and 
the remaining 5% is excreted unchanged in urine. The 
primary pathway involved in the metabolism of ondansetron 
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is initially indole ring hydroxylation which then undergoes 
glucoronide or sulfate conjugation. The enzyme involved in 
metabolism is cytochrome P-450 (CYP3A4, CUP2D6, 
CYPIA2). 
Hence drugs that induces or inhibits the enzymes 
cytochrome P450 has significant effect on the metabolism of 
the drugs and its duration of action. 
Phenytoin, rifampicin and carbamazepine induces the 
enzyme CYP3A4 and it significantly increases the clearance 
of the drug which reduces the plasma concentration and hence 
the half life of drug. 
The metabolic end products are conjugates of 7-
hydroxy and 8-hydroxy ondansetron. The end products are 
not metabolically active and they are excreted via kidneys.  
PREPARATION 
Oral -  4 or 8 mg of ondansetron Hcl. Dihydrate. 
PARENTERAL FORMULATION 
It is available as aqueous solution containing 2mg/ml of 
ondansetron  hydrochloride dihydrate, sodium chloride 9.0mg 
USP, citric and monohydrate 0.5mg USP, and 0.25mg of of 
 33 
sodium citrate dihydate USP, the shelf-life of the drug is 8 
years. It is compatible with 0.9% Normal Saline, Ringer 
Lactate and 5% dextrose containing solution. 
It is administered i.v over a period of 2-5 minutes. 
THERAPEUTIC USAGE 
Ondansetron is primarily an antiemetic used in the 
treatment of post-operative nausea and vomiting. It is the 
preferred antiemetic in patients undergoing highly  
emetogenic radiotherapy and chemotherapy with drugs such 
as high dose cisplatin. 
It is contraindicated in patients with known 
hypersensitivity to ondansetron. Hypersentive reaction have 
been reported in patients who are hypersensitive to other class 
of 5HT3 receptor antagonist. 
DOSAGE 
CHEMOTHERAPY INDUCED NAUSEA AND 
VOMITING(CINV) 
The recommended intravenous dosage of drugs for 
adults is single dose of 32mg iv or 0.15mg/kg. Single dose of 
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32mg is administered intravenously before the initiation of 
chemotherapy over a period of 15 minutes. In three dose 
regimen Subsequent doses (0.15mg/kg) are administered at 
4th and 8th hour after the first dose. 
In paediatric age group, three doses of 0.15mg/kg is 
given. After the initial dose of 0.15 mg/kg which is given half 
an hour before the initiation of chemotherapy, subsequent 
doses are given  4 and 8 hours apart. 
POST-OPERATIVE NAUSEA AND VOMITING 
The adult dosage for post-operative nausea and vomiting 
is 4mg ondansetron administered slow i.v. over 2-5 minutes 
before induction. 4mg is the fixed dose for patients weighing 
more than 40 kg.   
The recommended dosage of ondansetron is 0.1mg/kg 
for children weighing less than 40kg infused over a period of 
2-5 minutes. 
Geriatric dose is same as that recommended for adult 
patients. 
 
 35 
ADVERSE REACTION 
Headache, diarrhea, fever, akasthisia, Acute dystonic 
reactions are reported in patients receiving ondansetron  at a 
dose of 0.15mg/kg. 
CNS: 
Symptom similar to extrapyramidal reaction have been 
reported. Rarely Grand-mal seizures can occur. 
CARDIO-VASCULAR 
Chest Pain, Angina, ECG Changes, Tachycardia, 
Hypotension can occur. 
 
GASTRO INTESTINAL 
Constipation was reported in patients receiving 
ondansetron for Chemotherapy induced nausea and vomiting. 
HEPATIC 
Transient elevation of liver enzyme about two to three 
times normal is seen in patient with normal Liver function 
test who have undergone chemotherapy. 
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LOCAL REACTION 
Pain, redness, itching, and rash can occur at the site of 
inection. 
Other rare adverse effects include dizziness, musculo 
skeletal pain, sedation, swelling anxiety, pruritus, paresthesia, 
urinary retention and dysuria. 
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PHARMACOLOGY OF PALONOSETRON 
PALONOSETRON HYDROCHLORIDE 
Palonosetron is a second generation selective 5HT3 
receptor antagonist. palonosetron hydrochloride is chemically 
(3aS) -2-(CS)-1-Azabicyclo (2,2,2) Oct-3-yl) – 2,3,3a,4,5,6 – 
hexahydro-1-0x01Hbenz[de] isoquinolone hydrochloride. The 
molecular formula is expressed as C19H24N2O.Hcl.It has a 
estimated molecular weight of 332.87. The structural formula 
for palonosetron is  
 
     It has no isomers and it exist as a single structure .  
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PHYSICAL PROPERTIES 
It is a white crystalline powder. It is readily soluble in 
water and it does not exhibit isomerism inspite of two chiral 
centres. 
It is synthesized chemically in a five step process. It is 
a clear, sterile, colorless, buffered isotonic solution and it is 
non-pyrogenic. It is available in 5ml vial in the concentration 
of 0.25 mg palonosetron hydrochloride per ml of drug with 
other constituent such as 207.5 mg mannitol, citrate buffer, 
disodium edetate for intravenous administration. The pH 
varies between 4.5 to 5.5 
It is also available in 1.5ml vial with base drug of 0.075 
mg palonosetron containing 0.084mg palonosetron 
hydrochloride, 83 mg mannitol, citrate buffer and disodium 
edetate in water for intravenous administration. 
Shelf-life of the intravenous formulation of the drug is 
round 1-2 years. 
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MECHANISM OF ACTION 
Palonosetron is believed to be the most-effective 5HT3 
receptor antagonist due to its unique property of allosteric 
binding to 5HT3 receptors with the subsequent receptor 
internalization and negative co-operativity with neurokinin 1 
receptor. Palonosetron has a long half life of 40 hour with 30 
times higher receptor affinity than first generation. It has a 
very long half life of 40 hours. It binds to 5HT3 receptors 
located in the nerve terminals of vagus in the periphery and 
chemoreceptor trigger zone in the area postrema. 
PHARMACOKINETICS 
After intravenous administration of palonosetron, there 
is a initial decline in the plasma concentration of the drug 
followed by  slow elimination from the body. The volume of 
distribution of palonosetron is approximately 6.9 to 7.9 l/kg. 
62% of the drug is bound to plasma proteins. 
50% of palonosetron is metabolized primarily via 
hydroxylation to form two primary metabolites namely N-
oxide palonosetron and 6-8 hydroxy-palonosetron. Around 
1% of the primary metabolites of palonosetron have residual 
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antagonistic effects. palonosteron is primarily metabolized by 
CYP2D6 and also to a lesser extent by CYP3A4 and 
CYP1A2. 
The metabolic end products are eliminated via renal 
excretion. Total body clearance of palonosetron is 160 + 
35 ml/h/kg and the renal clearance of the drug was around 
66.5 + 18.2 ml/h/kg. The mean elimination half l ife of the 
drug is 40 hours which is due to the  low total body 
clearance and large volume of distribution of drug . Terminal 
elimination half life may extend beyond 100 hrs 
Age and gender do not affect the pharmacokinetics of 
palanoseteron. In patients with mild to moderate renal 
impairment pharmacokinetics of the drug is not much altered. 
severe renal impairment alters the pharmacokinetics and 
reduces renal clearance. Dose reduction is required in patients 
with severe hepatic impairment. 
THERAPEUTIC INDICATION 
Palonosetron is used in the prevention of nausea and 
vomiting following highly emetogenic chemotherapy.  
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It is used in the treatment as well as prophylaxis of 
post-operative nausea and vomiting. 
Contraindicated in patients with known hypersensitivity 
to the drug and also to other class of  5HT3 receptor 
antagonist. 
DRUG INTERACTIONS 
Study receptor knows that palonosetron is not an 
inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, 
CYP2D6, CYP2E1 and CYP3A4/5. Neither it induces the 
activity of CYP1A2, CYP2D6 or CYP3A4/5. 
Palonosetron does not interact with any 
chemotherapeutic drugs nor interfere with the anti-tumor 
activity of the drug. 
Palonosetron does not have any significant interaction 
with metoclopramide which  is a CYP2D6 inhibitor. 
SAFETY PROFILE 
Animal studies have shown no effect on fetal 
development at low doses. At high doses, fetal weight 
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reduction was observed. Hence it is not advisable during 
pregnancy. 
Palonosteron is not advised during lactation since it is 
not known wether the drug is excreted in Breast milk. 
DOSAGE 
CHEMOTHERAPY INDUCED NAUSEA AND 
VOMITING (CINV): 
The recommended dose is 250mg administered as a 
single dose 30 minutes before the initiation of chemotherapy.  
POST OPERATIVE NAUSEA AND VOMITING 
Single dosage of 0.075 mg palonosetron is administered 
intravenously over a period of 10 seconds before induction of 
anaesthesia  
ADVERSE REACTION 
Cardiovascular 
Hypotension and tachycardia can occur.Very rare 
complications include hypertension, angina, rhythm 
abnormalities, supraventricular extrasystoles and 
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prolongations of QT interval. The incidence of these 
complication is less than 1%. 
CENTRAL NERVOUS SYSTEM 
Headache, dizziness, paresthesia, insomnia, somnolence, 
anxiety. 
HEPATIC 
Transient elevation of liver enzymes such as AST & 
ALT can occur in patients receiving chemotherapy.  
GASTROINTESTINAL 
Constipation, dyspepsia, abdominal pain, dry mouth and 
flatulence.  
METABOLIC 
Hyper/hypokalemia, anorexia and hyperglycemia.  
DERMATOLOGIC 
Allergic dermatitis,  rash and irritation at the site of 
injection. 
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OTHERS  
Very rare complication include urinary retention, 
glycosuria, Arthralgia,  Hyperbilirubinemia, tinnitus, eye 
irritation. 
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REVIEW OF LITERATURE 
Yu Yil Kim et al., compared palonosetron with 
ondansetron in the prevention of post-operative nausea and 
vomiting in patients receiving intravenous patient 
controlled analgesia.This randomized interventional study 
was done in patients undergoing laparoscopic 
gynaecological surgery. Patients involved in study group 
were assigned randomly into two equal groups. One group 
received intravenous ondansetron 8mg iv bolus and 16 mg 
added to IV-PCA mixure. Another group received 
palonosetron 75 mcg i.v single bolus dose. The incidence 
of nausea, vomiting and side effects were recorded at 
2,24,48,& 72 hour post operatively. The results from the 
study showed that there was no difference in the incidence 
of Post Operative Nausea and Vomiting during 72 hr 
period. The incidence of vomiting in  ondansetron group 
was 18% compared to 4% in palonosetron group.It was 
observed that palonosetron was be superior to ondansetron 
in the preventing the incidence of post operative nausea 
and vomiting. 
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Moon Ye et al., compared the antiemetic effect of 
ondansetron and palonosetron in patients who underwent 
thyroidectomy and received opioid based PCA. In this 
prospective, randomized double blind study, consisting of 
100 patients, two groups consisting of 50 patients were 
randomly assigned to receive palonosetron 0.075 mg and 
ondansetron 8mg intravenous bolus followed by the 
addition of 16mg to PCA mixture containing fentanyl. 
Episodes of nausea, vomiting, severity of nausea, 
requirement of rescue antiemetic and adverse effects were 
observed over a period of 24 hours. There was no 
significant difference between two group during the first 2 
hours. But, during 2-24 hr, incidence of nausea and 
vomiting was lower in the palonosetron group than in the 
ondansetron group. The incidence of Post Operative 
Nausea and Vomiting in palonosetron group was 42% 
when compared to 62% in the ondansetron group. 
Palonosetron was found to be more effective than 
ondansetron in the prevention of Post Operative Nausea 
and Vomiting 2-24 hr after surgery. 
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Park SK, Cho EJ evaluated the efficacy of 
palonosetron and ondansetron in the prevention of Post 
Operative Nausea and Vomiting in female patients 
undergoing gynaecological laparoscopic surgeries. In a 
randomized double blind trial consisting of 90 patients, 
two groups of 45 patients each were randomnly assigned  to 
receive ondansetron 8mg intravenously and palonosetron 
0.075 mg intravenously before induction of anaesthesia. 
The occurrence of nausea and vomiting and severity of 
nausea was studied for a period of 24 hours. The incidence 
of Post Operative Nausea and Vomiting  was 42.2% in the 
palonosetron group compared to 66.7% in the ondansetron 
group. Palonosetron 0.075 mg was found to be more 
superior and efficacious than ondansetron in preventing 
Post Operative Nausea and Vomiting.  
Bajwa SS et al., in a prospective double blind study 
compared the antiemetic effect of ondansetron and 
palonosetron. Study was carried out in patients undergoing 
laparoscopic gynaecological surgery and subjects were 
randomnly assigned into two groups to receive intravenous 
palonosetron 75mcg and ondanseteron 8 mg intravenously. 
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The incidence of nausea was 20% in the ondansetron group 
when compared to 6.67% in the palonosetron group. The 
incidence of vomiting was 13.3% in the ondansetron group 
compared to 3.3% in the palonosetron group. There was no 
significant difference in the incidence of adverse effect 
between the two groups. Palonosetron was found to be 
superior and effective in the prevention of post operative 
nausea and vomiting when compared to ondansetron.  
Candiotti et al., conducted a placebo controlled study 
in a group of 574 patients who underwent gynaecological 
laparoscopic surgery to assess the efficacy and safety 
profile of three different doses of palonosetron. patients 
were stratified based on the risk factor and patients with > 
2 risk factors were assigned to receive one of the three 
doses of intravenous palonosteron (0.025 mg, 0.050 mg or 
0.075 mg)  before induction of anaesthesia. Complete 
response to the drug was observed over a period of  72 
hours in the post-operative period. Compared to placebo 
group, patients who received palonosetron were associated 
with less incidence of Post Operative Nausea and 
Vomiting. Complete response is defined when there is no 
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emetic episodes and no requirement of resue antiemetic. 
Complete response in placebo group was 26% when 
compared with 43% in palonosetron group in the first 0 -24 
hours whereas it was 41% in placebo and 49% in 
palonosetron group in 24-72 hours. The incidence and 
severity of nausea was comparatively low in the 
palonosetron group when compared to placebo group. Of 
the three doses, single dose of Palonosetron 0.075 mg was 
found to be effective in preventing the incidence of nausea 
and vomiting. 
Rojas C et al ., described the unique mechanism of 
interaction of palonosetron at the receptor level. They  
conducted experiments on receptor site saturation 
binding to examine competitive versus potential 
allosteric binding between Ondansetron, Palonosetron, 
Granisetron & 5HT3 receptor. on the basis of the 
experiment, it was found that palonosetron has unique 
mechanism of allosteric binding at the receptor level that 
differentiates it from other 5-HT3 receptor antagonist..  
Shadangi BK et al ., did a randomize double blind 
study to compare the efficacy of intravenous ondansetron 
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and palonoestron in the prevention  of post-operative 
nausea and vomiting. 90 patients undergoing general 
anaesthesia were divided into three groups containing 30 
members each. one group received placebo injection, the 
second group received ondansetron 8 mg iv and the third 
group received palonosetron 0.075 mg before induction 
of anaesthesia. Patients were followed up on this post -op 
period for the incidence of nausea and vomiting at 
1,2,6,12 and 24 hours. It was observed that there was no 
significant difference between Ondansetron and 
Palonosetron  in the incidence of vomiting but the 
incidence of nausea was significantly less in the 
palonosetron group than ondansetron group which was 
significantly less than palcebo group. Palonosetron was 
found to be more effective and superior than ondanse tron 
in the prevention of Post Operative Nausea and 
Vomiting. 
Blitz JD et al ., evaluated the efficacy of 
palonosetron with dexamethasone combination versus 
palonosetron alone in a randomized double blind study. 
The study group consist of 118 patients scheduled to 
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undergo laparoscopic surgeries.patients with more than 
three risk factors were included in the study.subjects 
were randomized into two groups of 59 each to receive a 
combination of 8 mg of dexamethasone plus 0.075mg of 
palonosetron and the other group received equivalent 
volume of saline plus 0.075mg of palonosetron. Patients 
were followed up for a period of 96 hours.the incidence 
of vomiting was 1.7% in the combination group whereas 
it was 6.8% in the group that received palonosetron 
alone. complete response (i.e no nausea and vomiting) to 
the drug under study was similar in both groups. There 
was no significant difference between the group that 
received palonosetron and dexamethasone combination 
mixture and the group that received only palonosetron .   
Chun HR et al., in a randomized double blinded 
study, evaluated the efficacy of palonosetron  in the 
prevention of nausea and vomiting.In this placebo 
controlled study,204 subjects who underwent elective 
surgery were randomly divided into two groups 
consisting of 102 subjects each.one group received 
palonosetron 0.075mg and the other group received 
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normal saline. patients were observed for a period of 72 
hours for the incidence of nausea and vomiting, severity 
of nausea and the use of rescue antiemetic. The incidence 
of post operative nausea and vomiting was 33% in 
palonosetron group and 47% in placebo group during 0 -
24 hours and when observed for a period of 72 hours, the 
incidence of post operative nausea and vomiting is 33% 
in palonosetron group and 52% in placebo group. The 
incidence of nausea was also lower in palonosetron 
group than the placebo group. The results obtained from 
the study proved that palonosetron significantly reduced 
the incidence of nausea and vomiting when compared to 
the placebo group. 
Laha et al., evaluated the antiemetic effect of 
intravenous Palonosetron versus intravenous 
Ondansetron in patients undergoing laparoscopic 
cholecystectomy. In this randomized single blinded study 
consisting of 49 subjects in each group ,the incidence  of 
post operative nausea and vomiting was observed over a 
period of 24 hours. The incidence at 0,2,6 and 24  hours 
was noted.The nausea score was comparable in the two 
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groups. complete response was seen in 28.6% patients in 
palonosetron group and 32.7% in Ondansetron group. 
The efficacy of palonosetron is comparable to 
ondansetron in the prevention of post operative nausea 
and vomiting. 
Sarbari swaika et al ., did a randomized double 
blinded study to compare the antiemetic effect of 
Ondansetron, Palonosetron and Ramosetron in patients 
undergoing laparasocopic cholecystestomy. This study 
was done in a group of 87 female patients randomly 
divided into three groups consisting of 29 subjects 
each.The three study groups were allocated to recive 
Ondansetron 8mg, Palonosetron 0.075mg and 
Ramosetron 0.3mg. The drug was administered at the end 
of surgery just before extubation. The patients were 
observed over a period of 24 hours and the complete 
response to nausea, vomiting and the requirement of 
rescue antiemetic was compared. It was found that the 
incidence of complete response was 65.5 % Ramosetron 
and 37.9% for  Palonosetron  and 34.5 % for 
Ondansetron. Hence a singinficant difference between 
 54 
the three groups was noted. When Ramosetron was 
compared with Palonosetron, it was found that  
Ramosetron is superior to Palonosetron in the prevention 
of nausea and vomiting.It was concluded from the study 
that 0.3mg of Ramosetron is better than 0.07mg of 
Palonosetron and  8mg Ondansetron in preventing the 
nausea and vomiting in the post operative period.  
Ahmed M AbdEI et al ., conducted a study to 
compare the efficacy of Palonosetron versus Ondansetron 
in the prevention of post operative nausea and vomiting 
in patients undergoing middle ear surgery.60 patients 
scheduled to undergo middle ear surgery were randomly 
divided into two groups consisting of 30 subjects each 
and they were allocated to receive Ondansetron 4mg 
intravenously and Palonosetron 0.25mg 
intravenously.The drug was administered just before the 
induction of anaesthesia and complete response to 
nausea, vomiting , severity of nausea and the requirment 
of rescue antiemetic was noted. It was observed that 28 
patients in Palonosetron group had complete response 
when compared to 22 patients in Ondansetron group. 4 
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patients in Palonosetron group required rescue 
antiemetic,whereas there was no requirement of  
antiemetic in Palonosetron group.The severity of nausea 
score was also less in Palonosetron group.It was 
concluded that Palonosetron was superior to Ondansetron 
with minimal side effects. 
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MATERIALS AND METHODS. 
This was a  randomized single blinded interventional 
study conducted at Government Kasturba Gandhi Hospital 
for Women and Children, Madras Medical College, 
Chennai. 
Instituition Ethical committee approval  was obtained 
before proceeding the study. Informed  written consent 
was obtained from all the 100 patients   who  were 
scheduled to undergo elective laparoscopic   gynaecological 
surgery.Information about the study type,the drug,its 
benefits and side effects were clearly explained and 
willingness of the patient to participate in  the study was 
documented. 
The Inclusion Criteria  
Age more than 18 years and  above,  
ASA PS 1&2. 
Patients undergoing elective surgery. 
Mallampati score 1&2  
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patients who are willing to undergo the study 
Patients who have given written informed consent.  
The Exclusion Criteria 
 Patients posted for emergency surgery.  
 Lack of written informed consent. 
Pregnant female. 
History of seizures and any neurological deficit.  
 History of motion sickness. 
 History of nausea and vomiting 24hrs prior to 
surgery.  
Patients with history of significant cardiovascular 
disease or rhythm  disturbance, liver, renal and endocrine  
abnormalities. 
METHOD 
Study population of 100 patients were  randomly 
assigned using statistical software into two groups of 50 
each.Patients were blinded about the study drug . Group 
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O received 2 ml of 4mg of Ondansetron and Group P 
received 2 ml of 0.075 mg of Palonosetron 
intravenously before the induction of Anesthesia. The 
drug was administered by the Anaesthesiologist who 
was involved in the assessment of the patient . In all the 
patients undergoing study,  standard anesthesia 
technique was followed.  
Study subjects were preloaded with 15 ml/kg  
Ringer Lactate intravenously.All  patients received 
premedication with Injection glycopyrrolate 0.004mg/kg 
and Injection  fentanyl 2  mcg/kg intravenously 30 mins  
prior to induction. The study drug   was administered 
according to the group. Anesthesia was induced with 
Injection thiopentone at a dose of 5 mg/kg .Intubation 
was facilitated with Injection atracurium 0.05 
mg/kg.Single use polyvinylchloride(PVC)  endotracheal 
tube was used for intubation.Anaesthesia was 
maintained with Oxygen and Nitrous oxide mixture in a 
ratio of 1:3 and the volatile anaesthetic used for 
maintenance was sevoflurane,the concentration of which 
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was titrated between 1-2% according to the depth of 
Anesthesia.  
Intraoperatively muscle relaxation was maintained 
with Injection Atracurium 0.01 mg/kg.Hemodynamic 
stability in the in tra operative period was monitored 
with heart rate,  electrocardiogram, blood pressure, pulse 
oximeter and end tidal CO2 monitor. 
Intraoperatively, the gas used for insufflation during 
laparoscopy was carbon dioxide. Intra abdominal pressure 
was maintained between 14-16mmHg.heart rate and blood 
pressure was maintained within 20% of the preoperative 
values. Neuromuscular blockade was reversed with 
Injection Neostigmine 0.04mg/kg and Injection 
Glycopyrrolate 0.004 mg/kg. In the immediate post 
operative period patient was shifted to recovery room for 
monitoring of vitals which includes heart 
rate,electrocardiogram and oxygen saturation . 
Patients were followed up  for the incidence  of  
nausea and vomiting immediately after extubation, during 
0-2 hours,2-24 hours and then over a period of 24-48 
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hours.patients were asked whether they had nausea and 
vomiting and other complaints like headache, dizziness 
and constipation were also recorded. 
Data obtained were analyzed and the statistical 
results were obtained using SPSS software. 
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OBSERVATION AND RESULTS 
Study population of 100 patients undergoing elective 
laparoscopic gynaecological surgeries were randomly divided 
into two groups.50 patients were allotted to group O 
receiving ondansetron and 50 patients were allotted to group 
P receiving palonosetron. 
Statistical analysis was done using SPSS package 
version 17 for windows.To compare intergroup differences, 
student’s T test was used and for categorical variables chi 
square or fisher’s exact test was used .A P value less than 
0.05 was considered to be statistically significant.                                  
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AGE DISTRIBUTION 
 Female patients aged 18 years and above were 
included in this study. 
AGE (YEARS) 
Group N Mean Std. Deviation P VALUE 
O 50 37.08 11.803  
0.596 
P 50 35.94 9.513 
Patients under 40 years of age comprised the majority 
of study population. The P value is 0.596 and there was no 
statistically significant difference in the age of the patients 
between the two study groups.  
The following chart shows age distribution in 
ondansetron group. 
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The following chart shows age distribution in palonosetron group.  
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WEIGHT DISTRIBUTION 
                                    WEIGHT(Kg) 
Group Mean Standard deviation P value 
O 55.16 9.63 0.162 
P 57.76 8.79 
 
The average distribution of weight in ondansetron group is 
55.16 and palonosetron group is 57.16.The P value based on 
student’s T test is 0.162 which is not statistically different. The two 
groups were comparable in weight distribution. 
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The following chart shows the distribution of weight in ondansetron group. 
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  The below chart shows the distribution of weight in Palonosetron group. 
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ASA PHYSICAL STATUS 
Patients belonging to the ASA physical status 1&2 were 
included in the study group. 
GROUP PS 1 PS 2 P VALUE 
O 37 13 
1.000 
P 37 13 
 
 
Based on T test the p value is 1.000.Hence there is no 
statistical difference between the two groups and they are 
comparable.  
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DURATION OF SURGERY 
The mean value of patient weight in ondansetron group is 
69.86  and 59.36  in palonosetron group.Based on T test, P value is 
0.089.There is no statistical difference between the two groups and 
hence they are comparable in terms of duration of surgery.  
DURATION OF SURGERY 
Group Mean Standard Deviation p Value 
O 69.86 32.07 
0.089 
P 59.36 28.92 
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The following chart shows the distribution of duration of surgery (minutes) in ondansetron group.  
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The following chart shows the distribution of duration of surgery (minutes) in Palonosetron group.  
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DURATION OF ANAESTHESIA 
DURATION OF ANAESTHESIA 
Group 
Mean 
(minutes) 
Standard 
deviation 
p value 
O 86.92 32.91 
0.182 
P 78.16 32.33 
 
Based on T test for equality of means the P value was found 
to be 0.182. There was no statistical significance between the two 
groups and the duration of anaesthesia was comparable between 
two groups. 
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The following charts shows the distribution of duration of  anaesthesia in ondansetron group. 
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The above charts shows the distribution of duration of anaesthesia in palonosetron group.  
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NAUSEA(0-2 HOURS) 
The incidence of nausea was 8 % in the ondansetron 
group when compared to  4% in the palonosetron group.with 
respect to the incidence of nausea in the first two hours of the 
post operative period,patients in O (ondansetron ) group had 
no significant difference in the incidence of nausea when 
compared to patients in the P (palonosetron) group with a P 
value of 0.395 by chi – square test. 
Comparision of incidence of nausea (0-2 HOURS)                                             
(chi – square test) 
NAUSEA(0-2 HOURS) 
GROUP 0 P TOTAL P VALUE 
+ 
4 
(8%) 
2 
(4%) 
6 
(6%) 
0.395 
- 
46 
(48.9%) 
48 
(51.1%) 
94 
(94%) 
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The following chart compares the incidence of nausea  
in the first two hours between the two study groups. 
 
 
 
 
 
Nausea (0-2Hours) 
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NAUSEA (2-24 HOURS) 
Three patients in group O reported nausea and  there 
was no incidence of nausea in the palonosetron group in 2-24 
hrs. 
Comparision of nausea in 2-24 hours. (chi-square test) 
NAUSEA (2-24 HOURS) 
GROUP O P P VALUE 
+ 3 (6%) 0 (0%) 
0.039 
_ 47 (94%) 50 (100%) 
The P value by chi-square test was 0.039 .  
 The difference in the incidence of nausea over a period 
of 2-24 hours was statistically significant with the incidence 
of 6% nausea in the ondansetron group compared to 
palonosetron group with no incidence of nausea.  
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The below chart compares the incidence of nausea 
during 2-24 hours between the two groups. 
 
Nausea (2-24Hours) 
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NAUSEA(24-48 HOURS) 
With the incidence of 4% (2 patients) nausea in 
ondansetron group compared to nil incidence of nausea in 
palonosetron group over a period of 24-48 hours, the P value 
was found to be 0.093 by chi-square test which implies that 
there is no statistically significant difference between the two 
groups. 
COMPARISION OF NAUSEA (24-48 HOURS) 
CHI SQUARE TEST 
GROUP O P P VALUE 
+ 2 (4%) 0 (0%) 
0.093 
 
- 48 (96%) 50 (100%) 
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The above chart shows the comparison of the incidence 
of nausea (24 to 48 hours) between the two groups. 
Nausea (24-48Hours) 
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VOMITING (0-2 HOURS) 
The incidence of vomiting in ondansetron group is 18% 
(9 Patients) and 8% (4 Patients) in palonosetron group. BY 
statistical analysis using chi-square test the p value was found 
to be 0.137 and hence there is no statistical difference in the 
incidence of vomiting in the immediate two hours following 
surgery.  
  
COMPARISON OF VOMITING( 0 TO 2 Hours) 
Group O P P VALUE 
+ 9 (18%) 4 (8%) 
0.137 
- 41  (82%) 46 (92%) 
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 (Vomiting 0-2 Hours) 
 
The above chart compares the incidence of vomiting in 
0-2 hours between the two groups. 
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VOMITING (2 TO 24 HOURS) 
With respect to the incidence of vomiting in 2 to 24 
hours, it was found that group O had 12% incidence  
(6 Patients) Whereas group P had 2% incidence (1 Patient). 
The difference in the incidence of vomiting between the two 
groups was significant with the P value of 0.050 (Chi – 
Square test).  
 
COMPARISON OF VOMITING (2 TO 24 HOURS): 
 (CHI – SQUARE TEST) 
 
VOMITING (2 TO 24 HOURS) 
GROUP O P P VALUE 
+ 6 (12%) 1 (2%) 
0.050 
- 44 (88%) 49 (98%) 
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The below chart compares the incidence of vomiting (2 – 24 
hours) between the two groups. 
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VOMITING (24 – 48 HOURS) 
In the analysis of incidence of vomiting over a period 
of 24 to 48 hours, it was found that the incidence is 6% in 
ondansetron group compared to nil incidence of vomiting in 
palonosetron group. The P value was found to be 0.039 and 
statistically significant difference between the two groups 
was observed.  
COMPARISON OF VOMITING (24 – 48 HOURS) 
 
 
VOMITING (24 TO 48 HOURS) 
GROUP O P P VALUE 
+ 3(6%) 0 (0%) 
0.039 
- 47 (94%) 50 (100%) 
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 (Vomiting 24-48 Hours) 
The above chart compares the incidence of vomiting 
(24 – 48 hours) between the two groups. 
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COMPLETE RESPONSE TO NAUSEA 
Complete response to nausea was found to be 84% in 
ondansetron group when compared to 96% in palonosetron 
group. With the P value of 0.046% ,significant difference in 
complete response to nausea was found between the two 
groups.   
 
COMPLETE RESPONSE TO NAUSEA 
  
COMPLETE RESPONSE (NAUSEA) 
GROUP O P P VALUE 
+ 8 (16%) 2 (4 %) 
0.046 
- 42 (84 %) 48 (96%) 
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The chart above shows the comparison of complete 
response to nausea between the ondansetron and palonosetron 
group.  
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COMPLETE RESPONSE TO VOMITING 
In comparing the complete response to vomiting, it was 
found that complete response was 66% (17 Patients) in 
ondansetron group and it was 90% (5 Patients) in 
palonosetron group. The P value by chi - square test was 
found to be 0.04 and it was a highly significant statistical 
difference between the two groups.  
 
COMPARISON OF COMPLETE RESPONSE TO 
VOMITING 
 (CHI – SQUARE TEST) 
 
COMPLETE RESPONSE TO VOMITING 
GROUP O P P VALUE 
+ 17 (34%) 5(10 %) 
0.004 
- 
33 (66 %) 
 
45 (90%) 
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The chart above shows the comparison of complete 
response to vomiting between the ondansetron and 
palonosetron group.  
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HEADACHE  
The incidence of headache was 8% (4 Patients) in 
ondansetron group and 6% (3 Patients) in palonosetron group. 
The two groups were comparable with P value of 0.695.  
 
HEADACHE 
GROUP O P P VALUE 
+ 4 (8%) 3 (6%) 
0.695 
 
- 46 (92%) 47 (94%) 
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The chart above shows the comparison of the incidence 
of headache between the ondansetron and palonosetron group.   
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DIZZINESS 
The incidence of dizziness was 6% (3 Patients) in both 
groups and there is no difference between the two groups 
with the P value of 1.000  
DIZZINESS 
GROUP O P P VALUE 
+ 3 (6%) 3 (6%) 
1.000 
 
- 47 (94%) 47 (94%) 
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The chart above shows the comparison of the incidence 
of dizziness between the ondansetron and palonosetron group.   
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CONSTIPATION 
We found that 4% of study subjects in ondansetron 
group had constipation whereas it was 2% in palonosetron 
group without any statistical difference(p value 0.558). 
 
CONSTIPATION 
GROUP O P P VALUE 
+ 2 (4%) 1 (2%) 
0.558 
- 48 (96%) 49 (98%) 
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 The chart above shows the comparison of 
incidence of constipation between the ondansetron and 
palonosetron group.  
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DISCUSSION 
Nausea and vomiting in the post operative period is a 
distressing complication following General Anesthesia. 
Incidence of Nausea and vomiting in the post operative period 
delays the discharge of the patient  undergoing day care 
surgery.Hence, the search for an effective antiemetic is 
reflected in the numerous studies that have been carried out 
so far. 
Since the mechanism and the pathway involved in 
nausea and vomiting is complex, no single drug can serve the 
purpose of completely preventing nausea and vomiting. The 
definite risk factors for the incidence of post operative nausea 
and vomiting include age, gender, duration and the type of 
anesthesia, obesity, non smokers, meniere’s disease , history 
of motion sickness and history of post operative nausea and 
vomiting. The increased usage of volatile anesthetics in 
General anaesthesia and opioids for post operative analgesia 
have increased the incidence of post operative nausea and 
vomiting. 
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Currently 5HT3 receptor antagonists are used as first 
line antiemetics in the prevention of post operative nausea 
and vomiting. Among serotonin receptor antagonist, 
ondansetron is the first drug of choice.  
In the present study, the efficacy of Palonosetron is 
compared with Ondansetron in the prevention of post 
operative nausea and vomiting in patients undergoing 
Laparoscopic gynaecological surgery.  The risk factor in the 
subjects include female patients, laparoscopy and 
gynaecological procedures  which is significantly associated 
with the incidence of nausea and vomiting. In the current era 
of minimally invasive surgery aiming at discharge on the day 
of surgery to minimize the cost and improve the quality of 
life , an effective anti emetic with greater potency and longer 
half life is required. As discussed above, Palonosetron meets 
the above criteria and it is superior among the serotonin (5 
HT3) receptor antagonist in terms of potency and half life.  
In this study, we compared the potency ,antiemetic 
effect and adverse effect profile of intravenous ondansetron 
and palonosetron. 
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.The incidence of vomiting is 34% in the ondansetron 
group when compared to 10% in the palonosetron group. The 
incidence of nausea is 16% in  Ondansetron group when 
compared to 4% in the Palonosetron group. 
We found that there was no difference in the incidence 
of nausea and vomiting between the groups in the first 0-2 
hours and it is significantly reduced in palonosetron group 
when compared to ondansetron group in the 2-48 hours. 
Bajwas et al reported that post operative vomiting 
occurred in 13.3% patients in ondansetron group ant it was 
3.3% in palonosetron group which is less when compared to 
our study .The incidence of vomiting in ondansetron and 
palonosetron group is 20% and 6% in their study when 
compared to 16% and 4%  respectively in our study. 
Reduction in nausea and emetic episodes in their study could 
be due to the use of Propofol for induction and maintenance 
of anaesthesia  which posses antiemetic effect even at very 
low doses. The results of their study correlates with our study 
which shows that palonosetron is superior to ondansetron in 
the prevention of nausea and vomiting. 
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Moon Y et al reported   that the incidence of PONV is 
62% in ondansetron group compared to 42% in palonosetron 
group in the study of patients who received opioid based 
patient controlled analgesia. The incidence of PONV is 
comparatively higher than in our study .This could be 
probably due to the  continuous use of opioids in the post 
operative period. The results obtained from the study is 
similar to our results which proves that palonosetron is 
superior to ondansetron in the prevention of post operative 
nausea and vomiting. 
We found that the incidence of adverse effect such as 
headache, constipation and dizziness is similar in both groups 
This correlates with the reports of other studies in relation to 
the adverse effect profile of the two drugs under study.  
There was no incidence of life threatening rhythm 
abnormalities like prolonged QT interval in our study. Food 
and drug administration has recently  issued black box alert 
for ondansetron in view of prolongation of QT interval. 
However,no such incidence have been reported in 
palonosetron so far. 
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Based on observation and analysis, we found that 
Palonosetron was found to be superior to ondansetron in the 
prevention of Nausea and vomiting. Second generation drug 
Palonosetron is unique among the serotonin receptor 
antagonist because of its allosteric binding at the receptor site  
with receptor internalization and a prolonged   duration of 
action of around 40 hours. 
 Hence, single intravenous dose of  0.075mg 
Palonosetron  before  induction of anaesthesia is the preferred 
drug of choice in the prevention of nausea and vomiting 
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CONCLUSION 
It is concluded that Intravenous Palonosetron (75 mcg) 
is more effective than intravenous Ondansetron(4 mg) in the 
prevention of post operative nausea and vomiting.The number 
and frequency of emetic episodes were significantly reduced. 
Hence palonosetron is superior to ondansetron and it is safe 
and reliable to use in the prevention of post operative nausea 
and vomiting. 
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DATE:                                     ROLL NO:                  
   
NAME:  
AGE:                          SEX:                      
  IP NO: 
DIAGNOSIS: 
PLANNED SURGICAL PROCEDURE: 
 
PRE OP ASSESSMENT: 
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                     H/O Documented Difficult Airway 
                      H/O previous surgeries 
 
Ht:                                                                       CVS:                              
    
Wt:                                                                       RS: 
AIRWAY:           MMC -                                                     IID      -                                               
DENTITION -    
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  Hb- 
  RFT- 
  LFT- 
  ECG- 
  CXR- 
PRE OP VITALS: 
PREMEDICATION DRUGS: 
STUDY DRUG:- 
INDUCTION:- 
INTUBATION:- 
MAINTENANCE:- 
REVERSAL DRUGS:- 
DURATION OF PROCEDURE:- 
 
 
 
 
MEASURES OF STUDY OUTCOME: 
INCIDENCE  OF PONV:  NAUSEA   VOMITING
 RESCUE DRUG. 
  0-2 HOURS 
  2-24HOURS 
  24-48HOURS 
DOSE OF OPIODS USED:- 
INTRA OP COMPLICATIONS:- 
POST OP COMPLICATIONS:-  
ADVERSE EFFECT:- HEADACHE/ NAUSEA/ VOMITING. 
 
 
 

INFORMATION TO PARTICIPANTS 
Investigator                    : Dr.L.PAVITHRA. 
Name of the Participant: 
Title :                    
“Comparative Evaluation of Intravenous Ondansetron(4mg) Versus  
Intravenous Palonosetron (75mcg) in the Prevention of Postoperative 
Nausea and Vomiting in Laparoscopic Gynaecological Surgeries ”  
You are invited to take part in this research study. We have got 
approval from the IEC. Your are asked to participate because you satisfy 
the eligibility criteria .We want to compare and study  the efficacy of 
intravenous ondansetron Versus intravenous palonosetron in the 
prevention of post operative nausea and vomiting. 
 
What is the Purpose of the Research:                                 
For laparoscopic gynaecological surgeries, antiemetic drug, either 
ondansetron or palonosetron will be given just before the induction of 
anaesthesia. The study is done to compare the efficacy of ondansetron 
and palonosetron with respect to                                           
1. Incidence of post operative nausea and vomiting. 
2. Post operative requirement of rescue anti emetic. 
 
 The Study Design: 
          All the patients in the study will be divided into two groups. 
 Group O - pre operative intravenous ondansetron. 
Group  P- pre operative intravenous palonosetron. 
All patients will be given general anaesthesia. 
  
Benefits                      
  Ondansetron and palonosetron given pre operatively before the 
induction of anesthesia reduces the incidence of post operative nausea 
and vomiting. 
Discomforts and risks 
                      Discomfort during injection such as pain,redness and 
burning may be present. 
 Other rare adverse events include headache, light headedness, 
transient elevation of liver enzymes and very rarely rythm disturbance. 
This intervention has been shown to be well tolerated as shown by 
previous studies. And if you do not want to participate you will have 
alternative  standard treatment and your safety is our prime concern. 
Time : 
Date : 
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Signature / Thumb Impression of Patient 
Patient Name: 
 
Signature of the Investigator : ____________________________ 
Name of the Investigator : ____________________________ 
 
 
 
            
 
 
 
 
                            PATIENT CONSENT FORM 
 
Study Title: “Comparative Evaluation of Intravenous Ondansetron 
(4mg) Versus  Intravenous Palonosetron (75mcg) in the Prevention of 
Postoperative Nausea and Vomiting in Laparoscopic Gynaecological 
Surgeries ” 
                                       
Study center:  Institute of Anaesthesiology and Critical Care,  
Govt Kasturba Gandhi Hospital for Women and Children,  
Madras Medical College, Chennai 600003.  
         
Participant Name :                            Age:           Sex:                I.P.No: 
 
                  
I confirm that I have understood the purpose and procedure of the 
above mentioned study.I have the opportunity to ask the question and all 
my questions and doubts have been answered to my satisfaction. 
I have been explained about the safety, advantage and disadvantage 
of the drugs used. 
I understand that my participation in the study is voluntary and that 
I am free to withdraw at anytime without giving any reason. 
I understand that the  investigator, regulatory authorities and the 
ethical committee will not need my permission to look at my health 
records both in respect to current study and any further research that may 
be conducted in relation to it, even if I withdraw from the study . I 
understand that my identity will not be revealed in any information 
released to third parties or published journal , unless as required under the 
law . I agree not to restrict the use of any data or results that arise from 
the study . 
 
 
Time:  
Date:      Signature / thumb impression of patient  
 
Place:                                          Patient name: 
 
 
Signature of the investigator: 
 
Name of the investigator: 
S.no Name Age Weight Diagnosis Surgery  Duration sxDuration anes0/P ASA 0-2/v 2-24/v 24-48/v 0-2/n 2-24/n 24-48/n headache dizziness constipation
1 Malar 24 48 kg PCOD DLAP 35 mins 50 mins O 1
2 kannagi 54 49 OVARIAN MASSDLAP 43 64 O 2 + +
3 seetha 36 45 ENDOMETRIOSISDLAP 55 73 O 1 +
4 murugavalli 35 66 PCOD LAP DRILLING 46 74 O 1 +
5 rani 58 47 AUB LAVH 122 134 O 2 +
6 ramila 28 56 INFERTILITY DHL 38 52 O 1 + +
7 thangam 28 59 FP LS 42 58 O 1
8 poonkodi 38 64 AUB DHL 55 63 O 1 + +
9 yazhisai 37 65 AUB DHL 57 71 O 1 +
10 azhagu 21 35 FP LS 44 58 O 1
11 ranjana 25 53 INFERTILITY DHL 53 62 O 1
12 reena 48 64 AUB DHL 58 69 O 2 + +
13 nila 52 66 DUB LAVH 102 122 O 2
14 radha 55 56 OVARIAN MASSDLAP 64 81 O 2 +
15 ranjitha 26 55 PCOD LAP DRILLING 83 102 O 1 +
16 renuka 33 60 INFERTILITY DHL 42 58 O 1 + +
17 yamini 27 47 ENDOMETRIOSISDHL 47 67 O 1
18 pallavi 47 48 AUB DLAP 53 62 O 2 +
19 santhya 25 53 INFERTILITY DHL 43 56 O 1 +
20 seetha 27 52 FP LS 38 43 O 1
21 sanjana 44 55 OVARIAN MASSDLAP 87 102 O 1 + +
22 devi 48 58 DUB LAVH 123 132 O 1 +
23 azhamelu 25 59 FP LS 38 54 O 1 +
24 annakili 59 66 OVARIAN MASSDLAP 121 144 O 2
25 maadhavi 43 65 FIBROID UTERUSLAP MYOMECTOMY94 108 O 1 +
26 manjula 44 69 AUB DHL 43 63 O 1
27 panjaangam 28 72 INFERTILITY DHL 52 72 O 1
28 valarmathi 27 74 FP LS 33 48 O 1
29 archana 19 54 PCOD LAP DRILLING 81 103 O 1 +
30 annakili 35 62 INFERTILITY DHL 42 64 O 1
31 banu 33 67 FP LS 53 66 O 1
32 kumari 34 55 AUB DHL 64 83 O 1 +
33 kanjana 38 54 ENDOMETRIOSISLAP DRILLING 121 132 O 1 + +
34 rekha 47 53 DUB LAVH 154 168 O 2
35 ambujam 44 58 AUB DHL 43 66 O 2
S.no Name Age Weight Diagnosis Surgery  Duration sxDuration anes0/P ASA 0-2/v 2-24/v 24-48/v 0-2/n 2-24/n 24-48/n headache dizziness constipation
36 selvi 26 54 FP LS 52 67 O 1 + +
37 shanthi 55 64 DUB LAVH 121 143 O 2 +
38 ragavi 58 67 OVARIAN MASSDLAP 93 107 O 2
39 meena 25 59 FP LS 62 74 O 1
40 uma 27 43 INFERTILITY DHL 51 77 O 1
41 maragatham 28 48 FIBROID UTERUSLAP MYOMECTOMY58 73 O 1
42 muniyammal 38 46 AUB DHL 62 82 O 1
43 solai 20 54 FP LS 43 66 O 1 +
44 valli 46 58 DUB LAVH 121 150 O 1
45 vanaja 47 52 DUB LAVH 104 125 O 1 + +
46 lakshmi 28 34 FP LS 33 53 O 1
47 vijaya 55 38 OVARIAN MASSLAVH 114 133 O 2 +
48 packiya 52 36 DUB LAVH 102 132 O 2
49 pangajam 22 38 PCOD LAP DRILLING 88 108 O 1 +
50 raani 35 58 FIBROID UTERUSMYOMECTOMY 120 132 P 1 +
S.no Name Age Weight Diagnosis Surgery  Duration sx Duration anes 0/P ASA 0-2/v 2-24/v 24-48/v 0-2/n 2-24/n 24-48/n headache dizziness constipation
1 subha 23 42 FP LS 38 54 P 1
2 thiruselvi 46 48 AUB DHL 44 63 P 1 +
3 muthukumari 45 51 AUB DHL 36 56 P 1 +
4 saveetha 23 47 INFERTILITY DHL 53 67 P 1
5 meena 26 48 FP LS 27 48 P 1
6 maragatham 22 55 ENDOMETRIOSIS LAP DRILLING 62 82 P 1
7 revathi 35 59 FIBROID UTERUS LAP MYOMECTOMY 53 86 P 1
8 raaji 34 54 AUB DHL 44 64 P 1
9 muthulakshmi 32 38 FP LS 28 43 P 1
10 viji 32 46 INFERTILITY DHL 54 72 P 1
11 saroja 44 49 AUB DHL 53 71 P 2 + +
12 poomayil 48 54 DUB LAVH 101 143 P 2
13 vasantha 54 55 INFERTILITY DHL 46 64 P 2 +
14 kutty 27 58 FP LS 33 46 P 1
15 vaani 33 49 AUB DHL 54 72 P 2
16 pooja 34 58 DUB LAVH 92 133 P 1
17 poongaothai 42 64 AUB DHL 44 57 P 2
18 mariammal 45 67 DUB LAVH 113 126 P 1
19 rameswari 25 49 FP LS 27 47 P 1 +
20 nandhini 28 53 FP LS 24 32 P 1
21 jeya 35 47 FIBROID UTERUS LAVH 77 110 P 1
22 janaki 37 58 AUB DHL 38 51 P 1
23 amala 44 69 AUB DHL 46 53 P 1 +
24 ambiga 48 72 DUB LAVH 93 132 P 2
25 sujatha 54 64 OVARIAN MASS DLAP 83 104 P 2
26 selvi 53 66 OVARIAN MASS DLAP 86 107 P 2 +
27 saadhana 45 68 AUB DHL 53 77 P 1
28 ramila 24 59 FP LS 32 48 P 1
29 aandal 26 64 FP LS 28 43 P 1 + +
30 anjana 23 67 INFERTILITY DHL 46 64 P 1
31 bavya 28 62 FIBROID UTERUS LAP MYOMECTOMY 92 113 P 1
32 tamilselvi 35 66 INFERTILITY DHL 46 62 P 1
33 malathi 36 67 DUB LAVH 121 141 P 1
34 moogambikai 44 53 AUB DHL 113 126 P 2
35 mallika 45 55 DUB LAVH 102 124 P 2
36 jeyashree 48 58 AUB DHL 33 48 P 2
S.no Name Age Weight Diagnosis Surgery  Duration sx Duration anes 0/P ASA 0-2/v 2-24/v 24-48/v 0-2/n 2-24/n 24-48/n headache dizziness constipation
37 raani 52 52 DUB LAVH 110 126 P 2 +
38 amirthavalli 34 49 INFERTILITY DHL 36 47 P 1
39 anandhalakshmi 37 47 DUB LAVH 121 134 P 1
40 shobana 36 69 AUB DHL 44 56 P 1
41 rajaathi 25 63 INFERTILITY DHL 38 48 P 1
42 meyyamai 45 56 AUB DHL 44 64 P 2
43 manjula 23 59 FP LS 33 48 P 1
44 malarvizhi 28 51 PCOD LAP DRILLING 81 114 P 1
45 arasi 35 54 AUB DHL 44 63 P 1 + +
46 prabhavathi 43 62 DUB LAVH 98 108 P 1 +
47 jeyanthi 28 71 FP LS 42 56 P 1
48 nirmala 34 74 ENDOMETRIOSIS DLAP 61 77 P 1
49 niranjana 29 72 FIBROID UTERUS LAP MYOMECTOMY 76 93 P 1
50 mythrayee 25 70 FP LS 25 45 P 1
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